• Lexaria extended material transfer agreement with PharmaCO through Dec. 31, 2026 for preclinical evaluation of DehydraTECH in GLP-1 programs.
• Extension keeps temporary exclusive license in effect while PharmaCO reviews Lexaria 2026 R&D results.
• Parties plan additional strategic discussions with PharmaCO clinical and business development teams as data from ongoing studies is delivered in Q3 and Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.